SOAT1 and myeloproliferative disorder: Although inhibiting CXCL4 alone does not fully reverse BM fibrosis, it significantly impacts the MPN phenotype, including inflammation, megakaryocyte dysplasia, and JAK-STAT activation, underscoring its importance in the pathophysiology of the disease [74].